JP2023540799A5 - - Google Patents
Info
- Publication number
- JP2023540799A5 JP2023540799A5 JP2023516074A JP2023516074A JP2023540799A5 JP 2023540799 A5 JP2023540799 A5 JP 2023540799A5 JP 2023516074 A JP2023516074 A JP 2023516074A JP 2023516074 A JP2023516074 A JP 2023516074A JP 2023540799 A5 JP2023540799 A5 JP 2023540799A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr3
- cdr1
- cdr2
- cancer
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077407P | 2020-09-11 | 2020-09-11 | |
| US202063077458P | 2020-09-11 | 2020-09-11 | |
| US202063077415P | 2020-09-11 | 2020-09-11 | |
| US63/077,415 | 2020-09-11 | ||
| US63/077,407 | 2020-09-11 | ||
| US63/077,458 | 2020-09-11 | ||
| US202163165050P | 2021-03-23 | 2021-03-23 | |
| US63/165,050 | 2021-03-23 | ||
| PCT/US2021/049769 WO2022056199A1 (en) | 2020-09-11 | 2021-09-10 | Multi-specific immune targeting molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540799A JP2023540799A (ja) | 2023-09-26 |
| JP2023540799A5 true JP2023540799A5 (https=) | 2024-09-19 |
Family
ID=80629898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516074A Pending JP2023540799A (ja) | 2020-09-11 | 2021-09-10 | 多重特異性免疫標的化分子及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220089737A1 (https=) |
| EP (1) | EP4211172A4 (https=) |
| JP (1) | JP2023540799A (https=) |
| KR (1) | KR20230084507A (https=) |
| AU (1) | AU2021338776A1 (https=) |
| CA (1) | CA3194752A1 (https=) |
| IL (1) | IL301242A (https=) |
| MX (1) | MX2023002945A (https=) |
| TW (1) | TW202227494A (https=) |
| UY (1) | UY39416A (https=) |
| WO (1) | WO2022056199A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10287346B2 (en) * | 2015-04-28 | 2019-05-14 | Mitsubishi Tanabe Pharma Corporation | RGMa binding protein and use thereof |
| MX2021010857A (es) | 2019-03-11 | 2021-12-15 | Janssen Biotech Inc | Anticuerpos biespecificos anti-v(beta17)/anti-cd123. |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| WO2022056197A1 (en) * | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| TW202227495A (zh) | 2020-09-11 | 2022-07-16 | 美商健生生物科技公司 | 用於調節β鏈介導之免疫的方法及組成物 |
| JP2024507180A (ja) * | 2021-02-16 | 2024-02-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体 |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| CN119255825A (zh) * | 2022-05-24 | 2025-01-03 | 第一三共株式会社 | 抗-cdh6抗体-药物缀合物的剂量方案 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024040220A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding fusion proteins |
| WO2024040228A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding proteins |
| EP4662239A1 (en) * | 2023-02-09 | 2025-12-17 | Janssen Biotech, Inc. | Anti-v beta 17/anti-cd123 bispecific antibodies |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| CN117187180B (zh) * | 2023-11-03 | 2024-01-26 | 四川大学 | 一种Th17细胞及其培养方法和应用及其诱导液 |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1877075A4 (en) * | 2005-04-25 | 2008-07-30 | Pfizer | ANTIBODY TO MYOSTATIN |
| US9315577B2 (en) * | 2008-05-01 | 2016-04-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US9790274B2 (en) * | 2013-03-14 | 2017-10-17 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases |
| SG10201913782UA (en) * | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| CA2979759C (en) * | 2015-04-16 | 2023-08-08 | Eisai R&D Management Co., Ltd. | Anti-human notch4 antibody |
| JO3711B1 (ar) * | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US10800843B2 (en) * | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| EP3356415B1 (en) * | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| US11370830B2 (en) * | 2017-04-07 | 2022-06-28 | The Rockefeller University | Neutralizing antibodies that bind to the zika virus domain III envelope region |
| JP7404252B2 (ja) * | 2017-11-08 | 2023-12-25 | ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド | 生体分子のコンジュゲートおよびその使用 |
| MX2020014243A (es) * | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| CA3105448A1 (en) * | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2595980B (en) * | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| MX2021010857A (es) * | 2019-03-11 | 2021-12-15 | Janssen Biotech Inc | Anticuerpos biespecificos anti-v(beta17)/anti-cd123. |
| EP3986936A4 (en) * | 2019-06-21 | 2023-03-15 | Single Cell Technology, Inc. | ANTI-TIGIT ANTIBODIES |
| AU2020359070A1 (en) * | 2019-10-03 | 2022-04-21 | Janssen Biotech, Inc. | Methods for producing biotherapeutics with increased stability by sequence optimization |
| AU2021225870A1 (en) * | 2020-02-27 | 2022-10-20 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
-
2021
- 2021-09-10 US US17/472,237 patent/US20220089737A1/en not_active Abandoned
- 2021-09-10 CA CA3194752A patent/CA3194752A1/en active Pending
- 2021-09-10 WO PCT/US2021/049769 patent/WO2022056199A1/en not_active Ceased
- 2021-09-10 KR KR1020237012237A patent/KR20230084507A/ko active Pending
- 2021-09-10 EP EP21867638.5A patent/EP4211172A4/en active Pending
- 2021-09-10 UY UY0001039416A patent/UY39416A/es unknown
- 2021-09-10 JP JP2023516074A patent/JP2023540799A/ja active Pending
- 2021-09-10 TW TW110133804A patent/TW202227494A/zh unknown
- 2021-09-10 IL IL301242A patent/IL301242A/en unknown
- 2021-09-10 AU AU2021338776A patent/AU2021338776A1/en not_active Abandoned
- 2021-09-10 MX MX2023002945A patent/MX2023002945A/es unknown
-
2024
- 2024-10-10 US US18/912,192 patent/US20250043004A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540799A5 (https=) | ||
| Weiner et al. | Monoclonal antibodies for cancer immunotherapy | |
| JP2015214582A5 (https=) | ||
| JP2018518454A5 (https=) | ||
| JP2016502504A5 (https=) | ||
| JP2015534577A5 (https=) | ||
| JP2014158469A5 (https=) | ||
| JP2018535692A5 (https=) | ||
| JP2018515137A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2015532292A5 (https=) | ||
| JP2018027952A5 (https=) | ||
| MA39070A1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
| JP2019517512A5 (https=) | ||
| JP2017536340A5 (https=) | ||
| MX2017014740A (es) | Métodos de tratamiento del cáncer con anticuerpos anti-ox40. | |
| JP2023540796A5 (https=) | ||
| JP2019506398A5 (https=) | ||
| JP2019506403A5 (https=) | ||
| NZ604007A (en) | Monoclonal antibodies against her2 epitope | |
| MX2017015937A (es) | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. | |
| AR062840A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2) | |
| MX2022002524A (es) | Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer. | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения |